Biotechnology & Pharmaceuticals Industry ESG Material Mapping

HC-BP-240a.1Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index

HC-BP-240a.2List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)

HC-BP-240b.1Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period

HC-BP-240b.2Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year

HC-BP-240b.3Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year

FB-RN-430a.2 Percentage of (1) eggs that originated from a cage-free environment and (2) pork that was produced without the use of gestation crates

FB-RN-430a.3Discussion of strategy to manage environmental and social risks within the supply chain, including animal welfare

HC-BP-510a.1Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery

HC-BP-510a.2Description of code of ethics governing interactions with health care professionals

HC-BP-260a.1Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting

HC-BP-260a.2Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products

HC-BP-260a.3Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products

HC-BP-250a.1List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database

HC-BP-250a.2Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System

HC-BP-250a.3Number of recalls issued, total units recalled

HC-BP-250a.4Total amount of product accepted for take-back, reuse, or disposal

HC-BP-250a.5Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type

HC-BP-330a.1Discussion of talent recruitment and retention efforts for scientists and research and development personnel

HC-BP-330a.2(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others

HC-BP-270a.1Total amount of monetary losses as a result of legal proceedings associated with false marketing claims

HC-BP-270a.2Description of code of ethics governing promotion of off-label use of products

HC-BP-210a.1Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials

HC-BP-210a.2Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)

HC-BP-210a.3Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries

HC-BP-430a.1Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients